Journal
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
Volume 28, Issue 8, Pages 941-955Publisher
SPRINGER JAPAN KK
DOI: 10.1007/s10147-023-02360-8
Keywords
Advanced solid tumor; Clinical practice guideline; Tumor mutation burden-high (TMB-H); Immunotherapy; PD-1; PD-L1 inhibitor
Categories
Ask authors/readers for more resources
The development of novel antitumor agents and biomarkers has improved survival in different tumor types. Immune checkpoint inhibitors have shown efficacy in patients with TMB-H solid tumors, leading to the need for guidelines prioritized for these patients. This guideline provides recommendations for properly testing TMB and selecting patients who can benefit from immunotherapy.
The development of novel antitumor agents and accompanying biomarkers has improved survival across several tumor types. Previously, we developed recommendations for tumor-agnostic treatments in patients with solid tumors with DNA mismatch repair deficient or neurotrophic receptor tyrosine kinase fusions. Recently, immune checkpoint inhibitors have shown efficacy in patient with tumor mutation burden-high (TMB-H) solid tumors and have been established as a third tumor-agnostic agent, making it necessary to develop the guideline prioritized for these patients. Clinical questions regarding medical care were formulated for patients with TMB-H advanced solid tumors. Relevant publications were searched by PubMed and Cochrane Database. Critical publications and conference reports were added manually. Systematic reviews were performed for each clinical question for the purpose of developing clinical recommendations. The committee members identified by Japan Society of Clinical Oncology (JSCO), Japanese Society of Medical Oncology (JSMO), and Japanese society of pediatric hematology/oncology (JSPHO) voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other related factors. Thereafter, a peer review by experts nominated from JSCO, JSMO, and JSPHO, and the public comments among all societies' members was done. The current guideline describes three clinical questions and seven recommendations for whom, when, and how TMB should be tested, and what is recommended for patients with TMB-H advanced solid tumors. In this guideline, the committee proposed seven recommendations for performing TMB testing properly to select patients who are likely to benefit from immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available